Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Annovis Bio ( (ANVS) ) is now available.
On June 17, 2025, Annovis Bio, Inc. held its Annual Meeting of Stockholders virtually, where two proposals were submitted and approved. The first proposal involved the election of five directors to the company’s board, while the second proposal ratified the appointment of Ernst & Young LLP as the company’s independent auditors.
The most recent analyst rating on (ANVS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.
Spark’s Take on ANVS Stock
According to Spark, TipRanks’ AI Analyst, ANVS is a Underperform.
Annovis Bio’s overall stock score reflects significant financial challenges with zero revenue and consistent losses, offset slightly by a debt-free balance sheet. Technical indicators suggest a bearish outlook, and valuation metrics are unattractive. Corporate events create a mixed picture, with regulatory compliance issues countered by progress in drug development. The stock remains speculative, relying heavily on future R&D success.
To see Spark’s full report on ANVS stock, click here.
More about Annovis Bio
Average Trading Volume: 450,693
Technical Sentiment Signal: Sell
Current Market Cap: $50.66M
See more insights into ANVS stock on TipRanks’ Stock Analysis page.